帝博硅胶制品厂,20年硅胶生产经验专业定制硅胶制品,硅橡胶制品,饰品,配件,日用品等硅胶产品,资深老工程师现场监督,1天出样,3-5天即可送货,东莞硅胶定制认准帝博,咨询热线:4000-0866-562
更新时间：2025-06-24 直达：www.dgdb88.cn
轻流-轻量级、可自定义的管理系统搭建平台，无需代码开发即可如搭积木般快速、灵活地创造属于你的定制化管理系统，轻松实现多元业务场景的数字化管理。非IT人员也可以自定义搭建CRM、ERP、EHS、项目管理等系统。
炎黄梅氏网,炎黄梅姓网,梅氏宗亲网,梅氏寻亲网,国内各地市梅氏宗亲联谊会,炎黄梅氏网打造专业的中国梅氏宗亲网。
苏州欧美特塑胶有限公司是一家专业从事塑料物流容器销售企业，位于江苏省苏州市。
暂无描述...
茉莉科技是汽车新流通解决方案服务商。茉莉科技致力于汽车资产全生命周期管理，通过汽车使用权交易改变传统汽车买卖模式，创建符合中国消费者利益的拥车模式，推动汽车流通行业升级。
主机汇-国内5强虚拟主机服务商.十年品牌虚拟主机和域名注册精品服务,为全球12万用户提供专业虚拟主机,域名注册,VPS主机租用,企业邮箱服务.提供免费虚拟主机;超值低价主机月付;专业Linux主机;成都虚拟主机注册中心
中铁四局集团投资运营有限公司
WestVacBiopharmaisfoundedbyAcademicianWeiYuquanfromWestChinaHospitalofSichuanUniversity,togetherwith10scientistsfromStateKeyLaboratoryofBiotherapy(SKLB).ItsheadquarterislocatedintheInternationalBio-Town,Chengdu.TheCEOofWestVacBiopharmaisProf.WeiYuquan,whoistheAcademicianofChineseAcademyofSciencesaswellastheDirectorofStateKeyLaboratoryofBiotherapy.WestVaciscommittedtoexploringthelatestbiotherapytechnologiesformajordiseases,includinginfectiousdiseases,malignanttumors,cardiovasculardiseases,andsoon.IthasattachedgreatimportanceintheResearchandDevelopment(R&D)ofCOVID-19vaccineespeciallyandbuildingaCOVID-19vaccineproductionplatform.StateKeyLaboratoryofBiotherapy(SKLB)wasestablishedbytheMinistryofSciencesandTechnologyofChinain2005andbecameoneoftheNationalR&DPlatformsforNovelDrugsfoundedbytheMinistriesofSciencesandTechnologyaswellasthatofHealthofChinain2008.ItisalsosupportedbyNationalCollaborativeInnovationProgramandhasbecometheNationalCollaborativeInnovationCenterforBiotherapysince2013.WestChinaHospitalofSichuanUniversity，foundedin1892,istheNationalCenterforDiagnosisandTreatmentofSevereandCriticalDiseasesinWesternChina.Itisalsotheworld’slargestcomprehensivehospitalcomplexlocatedinonecampusarea.RelyingonthemedicalresourcesofStateKeyLaboratoryofBiotherapyandWestChinaMedicalCenter,WestVachasadoptedrecombinantproteinmethodologytodeveloptheCOVID-19vaccine.Becauseofthesafetyoftheproteinvaccine,itisalsotheonlyCOVID-19vaccineapprovedfortheuseinchildrenover3yearsoldinChina.ThevaccinewasapprovedbytheNationalMedicalProductsAdministrationforclinicaltrialsonAugust21,2020.PhaseI/IIclinicaltrialshavebeencompleted,andphaseIIIclinicaltrialsarebeingcarriedoutinNepal,Kenya,Japanandothercountries.Thevaccinetargetsthespikeproteinbindingdomain(S-RBD)ofSARS-CoV-2,producingneutralizingantibodiestoblockCOVID-19infectionofhumancells.TheresultwaspublishedonNature,theworld’sfamousscientificjournalonJuly29th,2020.IthasalsobeenthefirstpaperofCOVIDvaccinepublishedbyNaturesincethepandemicoutbreak.TheS-RBDgeneoftheCOVID-19virusisintroducedintotheinsectcells,whichwereusedasafactorytoproducehigh-qualityrecombinantvaccineproteinandthendoesrefinedpurification.Suchtechnologyiseasytobemass-producedandbroughttothemarket.WestVacBiopharmaiscommittedtobecomingtheworld`sleadingvaccineandimmunotherapyplatform.
暂无描述...